The Principals have made investments in the following pharmaceutical companies:

 

Amarin Corporation plc   

(NASDAQ ticker: AMRN)| www.amarincorp.com | is a biopharmaceutical company addressing cardiovascular and central nervous system diseases.

 

 

Auspex Pharmaceuticals, Inc. www.auspexpharma.com | is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs. 

 

Cerus Corporation (ticker: CERS) | www.cerus.com | is marketing and developing systems to inactivate viruses, bacteria and other pathogens in blood components for transfusion. The company also is focused on developing new vaccine technologies.

 

Clarus Therapeutics, Inc.www.clarustherapeutics.com | is developing new approaches for hormone replacement therapy.

The Medicines Company (ticker: MDCO) | www.themedicinescompany.com | is a licensing-focused, drug development company currently marketing AngiomaxT, a novel anti-coagulant.



NeuroTherapeutics Pharma, Inc.

| www.ntprx.com | is focused on the development of novel therapeutics for the treatment of CNS disorders.

 

 

Ocera Therapeutics, Inc.  | www.oceratherapeutics.com  | is focused on the development of pharmaceutical products for gastrointestinal and liver diseases.

 

 

Oriel Therapeutics, Inc.  | www.orieltherapeutics.com | is a respiratory drug delivery company developing dry powder delivery systems for the treatment of asthma and COPD.

 

 

Quinnova Pharmaceuticals, Inc.  |  www.quinnova.com  | is a specialty pharmaceutical company focused on the development and commercialization of prescription drug products based on innovative drug delivery platforms for the dermatology market. 

 

 

Solstice Neurosciences, Inc. | www.solsticeneuro.com |

manufactures and markets MyoblocT, an FDA approved formulation of Botulinum Toxin type B, for the treatment of neurologically-induced muscle spasms.

 

 

Zogenix, Inc.  | www.zogenix.com | is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain, with an initial focus on Intraject® sumatriptan, a needle-free migraine treatment.
 
 
    © 2010 Thomas, McNerney & Partners - All Rights Reserved.
|